Analyst Price Target is $26.75
▲ +2.85% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Galapagos in the last 3 months. The average price target is $26.75, with a high forecast of $31.00 and a low forecast of $22.00. The average price target represents a 2.85% upside from the last price of $26.01.
Current Consensus is
Strong Sell
The current consensus among 9 investment analysts is to strong sell stock in Galapagos. This rating changed within the last month from a Reduce consensus rating.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Read More